Literature DB >> 27671875

Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets.

Tengfei Li1, Matthias Vandesquille2, Fani Koukouli3, Clémence Dudeffant4, Ihsen Youssef5, Pascal Lenormand6, Christelle Ganneau7, Uwe Maskos3, Christian Czech8, Fiona Grueninger8, Charles Duyckaerts5, Marc Dhenain9, Sylvie Bay7, Benoît Delatour5, Pierre Lafaye10.   

Abstract

Detection of intracerebral targets with imaging probes is challenging due to the non-permissive nature of blood-brain barrier (BBB). The present work describes two novel single-domain antibodies (VHHs or nanobodies) that specifically recognize extracellular amyloid deposits and intracellular tau neurofibrillary tangles, the two core lesions of Alzheimer's disease (AD). Following intravenous administration in transgenic mouse models of AD, in vivo real-time two-photon microscopy showed gradual extravasation of the VHHs across the BBB, diffusion in the parenchyma and labeling of amyloid deposits and neurofibrillary tangles. Our results demonstrate that VHHs can be used as specific BBB-permeable probes for both extracellular and intracellular brain targets and suggest new avenues for therapeutic and diagnostic applications in neurology.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Abeta; Alzheimer's disease; Blood-brain barrier; In vivo imaging; Tau; VHH

Mesh:

Substances:

Year:  2016        PMID: 27671875     DOI: 10.1016/j.jconrel.2016.09.019

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  28 in total

1.  Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease.

Authors:  Crystal M Vander Zanden; Eva Y Chi
Journal:  J Pharm Sci       Date:  2019-10-21       Impact factor: 3.534

2.  Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer's disease.

Authors:  Matthias Vandesquille; Tengfei Li; Chrystelle Po; Christelle Ganneau; Pascal Lenormand; Clémence Dudeffant; Christian Czech; Fiona Grueninger; Charles Duyckaerts; Benoît Delatour; Marc Dhenain; Pierre Lafaye; Sylvie Bay
Journal:  MAbs       Date:  2017-06-28       Impact factor: 5.857

Review 3.  Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review.

Authors:  Yang Gao; Jianwei Zhu; Huili Lu
Journal:  Drug Deliv Transl Res       Date:  2020-11-05       Impact factor: 4.617

Review 4.  Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.

Authors:  Isabelle Landrieu; Elian Dupré; Davy Sinnaeve; Léa El Hajjar; Caroline Smet-Nocca
Journal:  Front Chem       Date:  2022-05-12       Impact factor: 5.545

Review 5.  Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside.

Authors:  Parisa Shamshiripour; Fahimeh Hajiahmadi; Shahla Lotfi; Niloofar Robab Esmaeili; Amir Zare; Mahzad Akbarpour; Davoud Ahmadvand
Journal:  Front Immunol       Date:  2022-06-10       Impact factor: 8.786

Review 6.  Tau Immunotherapies for Alzheimer's Disease and Related Tauopathies: Progress and Potential Pitfalls.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 7.  Camelid Single-Domain Antibodies for the Development of Potent Diagnosis Platforms.

Authors:  Nairo Brilhante-da-Silva; Rosa Maria de Oliveira Sousa; Andrelisse Arruda; Eliza Lima Dos Santos; Anna Carolina Machado Marinho; Rodrigo Guerino Stabeli; Carla Freire Celedonio Fernandes; Soraya Dos Santos Pereira
Journal:  Mol Diagn Ther       Date:  2021-06-19       Impact factor: 4.074

Review 8.  Application of Antibody Fragments Against Aβ With Emphasis on Combined Application With Nanoparticles in Alzheimer's Disease.

Authors:  Zhi-Ting Sun; Chi Ma; Guang-Jian Li; Xiang-Yu Zheng; Yi-Tong Hao; Yu Yang; Xu Wang
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

9.  Detection of retinal and blood Aβ oligomers with nanobodies.

Authors:  Umma Habiba; Joseph Descallar; Fabian Kreilaus; Utpal K Adhikari; Sachin Kumar; John W Morley; Bang V Bui; Maya Koronyo-Hamaoui; Mourad Tayebi
Journal:  Alzheimers Dement (Amst)       Date:  2021-05-06

Review 10.  Current Status of Clinical Trials on Tau Immunotherapies.

Authors:  Changyi Ji; Einar M Sigurdsson
Journal:  Drugs       Date:  2021-06-08       Impact factor: 11.431

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.